Citius Pharmaceuticals to Present Update on Mino-Lok and Other Therapies at the Virtual Investor Conferences Small and Microcap Showcase on February 4
02/02/2021 - 08:00 AM
CRANFORD, N.J. , Feb. 2, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, will present at the upcoming Virtual Investor Conferences Small and Microcap Showcase on Thursday, February 4, 2021 . Citius Chairman of the Board Leonard Mazur will present an update on the Company's lead product candidate MinoLok, currently in Phase 3 trials, and an overview of three other active programs.
Date: Thursday, February 4, 2021 Time: 1:00 p.m. ET Link: https://bit.ly/3brvZ8w
This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at www.virtualinvestorconferences.com.
About Citius Pharmaceuticals, Inc. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit www.citiuspharma.com .
Contact: Andrew Scott Vice President, Corporate Development (O) 908-967-6677 x105 (M) 646-522-8410 ascott@citiuspharma.com
View original content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-update-on-mino-lok-and-other-therapies-at-the-virtual-investor-conferences-small-and-microcap-showcase-on-february-4-301219900.html
SOURCE Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals Inc
CTXR Rankings
#3945 Ranked by Stock Gains
CTXR Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
Country
US
City
Cranford
About CTXR
citius pharmaceuticals, inc., a specialty pharmaceutical company, develops and commercializes critical care products. it primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. the company is developing mino-lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in phase iii clinical trials; mino-wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; halo-lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and novecite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. citius pharmaceuticals, inc. was founded in 2007 and is headquartered in cranford, new jersey.